The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The third ‘Downton Abbey’ film honors the late Dame Maggie Smith and her iconic portrayal of Violet Crawley. The drug is ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...

Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...